ADP-ribosyl Cyclase 1

"ADP-ribosyl Cyclase 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A bifunctional enzyme that catalyzes the synthesis and HYDROLYSIS of CYCLIC ADP-RIBOSE (cADPR) from NAD+ to ADP-RIBOSE. It is a cell surface molecule which is predominantly expressed on LYMPHOID CELLS and MYELOID CELLS.

Descriptor ID	D051997
MeSH Number(s)	D08.811.277.450.430.400.060.500 D12.776.543.550.045
Concept/Terms	ADP-ribosyl Cyclase 1 ADP-ribosyl Cyclase 1 1, ADP-ribosyl Cyclase ADP ribosyl Cyclase 1 Cyclase 1, ADP-ribosyl T10 Antigen Antigen, T10 NIM-R5 Antigen NIM R5 Antigen CD38 Antigens ADPR Cyclase T10 Cyclase T10, ADPR Acute Lymphoblastic Leukemia Cells Antigen CD38 Lymphocyte Differentiation Antigen CD38 Antigens, CD38 CD38 Antigen ADPR Cyclase CD38 CD38, ADPR Cyclase Cyclase CD38, ADPR

Below are MeSH descriptors whose meaning is more general than "ADP-ribosyl Cyclase 1".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Hydrolases [D08.811.277]
Glycoside Hydrolases [D08.811.277.450]
N-Glycosyl Hydrolases [D08.811.277.450.430]
NAD+ Nucleosidase [D08.811.277.450.430.400]
ADP-ribosyl Cyclase [D08.811.277.450.430.400.060]
ADP-ribosyl Cyclase 1 [D08.811.277.450.430.400.060.500]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Membrane Glycoproteins [D12.776.543.550]
ADP-ribosyl Cyclase 1 [D12.776.543.550.045]

Below are MeSH descriptors whose meaning is related to "ADP-ribosyl Cyclase 1".

Below are MeSH descriptors whose meaning is more specific than "ADP-ribosyl Cyclase 1".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "ADP-ribosyl Cyclase 1" by people in this website by year, and whether "ADP-ribosyl Cyclase 1" was a major or minor topic of these publications.

Bar chart showing 28 publications over 18 distinct years, with a maximum of 5 publications in 2004

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	0	1	1
2002	0	1	1
2003	0	1	1
2004	0	5	5
2005	2	1	3
2006	2	0	2
2007	0	2	2
2008	1	0	1
2009	0	1	1
2014	1	0	1
2015	0	1	1
2016	1	0	1
2018	1	0	1
2019	1	0	1
2020	1	1	2
2021	0	1	1
2023	0	2	2
2024	1	0	1

Below are the most recent publications written about "ADP-ribosyl Cyclase 1" by people in Profiles.

Dogan S, Walseth TF, Guvenc Tuna B, U?ar E, Kannan MS, Deshpande DA. CD38/cADPR-mediated calcium signaling in a human myometrial smooth muscle cell line, PHM1. IUBMB Life. 2024 12; 76(12):1223-1233.

View in: PubMed
Portuguese AJ, Fang M, Tuazon SA, Pont M, Qu X, Shasha C, Comstock M, Lyons J, Cole G, Newell EW, Glynn E, Soma LA, Green DJ. Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma. Blood Adv. 2023 12 12; 7(23):7235-7238.

View in: PubMed
Isabelle C, Johnson WT, McConnell K, Vogel A, Brammer JE, Boles A, Keller R, Sindaco P, Nisenfeld L, Uppal G, Nikbakht N, Calabretta B, Porazzi P, Gong J, Chakravarti N, Porcu P, Mishra A. Preclinical evaluation of anti-CD38 therapy in mature T-cell neoplasms. Blood Adv. 2023 07 25; 7(14):3637-3641.

View in: PubMed
Kinder M, Bahlis NJ, Malavasi F, De Goeij B, Babich A, Sendecki J, Rusbuldt J, Bellew K, Kane C, Van de Donk NWCJ. Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma. Haematologica. 2021 07 01; 106(7):2004-2008.

View in: PubMed
Jiao Y, Yi M, Xu L, Chu Q, Yan Y, Luo S, Wu K. CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers. Expert Opin Investig Drugs. 2020 Nov; 29(11):1295-1308.

View in: PubMed
Guedes AG, Dileepan M, Jude JA, Deshpande DA, Walseth TF, Kannan MS. Role of CD38/cADPR signaling in obstructive pulmonary diseases. Curr Opin Pharmacol. 2020 04; 51:29-33.

View in: PubMed
O'Steen S, Comstock ML, Orozco JJ, Hamlin DK, Wilbur DS, Jones JC, Kenoyer A, Nartea ME, Lin Y, Miller BW, Gooley TA, Tuazon SA, Till BG, Gopal AK, Sandmaier BM, Press OW, Green DJ. The a-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model. Blood. 2019 10 10; 134(15):1247-1256.

View in: PubMed
Deshpande DA, Guedes AGP, Graeff R, Dogan S, Subramanian S, Walseth TF, Kannan MS. CD38/cADPR Signaling Pathway in Airway Disease: Regulatory Mechanisms. Mediators Inflamm. 2018; 2018:8942042.

View in: PubMed
Deshpande DA, Guedes AGP, Lund FE, Subramanian S, Walseth TF, Kannan MS. CD38 in the pathogenesis of allergic airway disease: Potential therapeutic targets. Pharmacol Ther. 2017 Apr; 172:116-126.

View in: PubMed
d'Ettorre G, Ceccarelli G, Andreotti M, Selvaggi C, Giustini N, Serafino S, Schietroma I, Nunnari G, Antonelli G, Vullo V, Scagnolari C. Analysis of Th17 and Tc17 Frequencies and Antiviral Defenses in Gut-Associated Lymphoid Tissue of Chronic HIV-1 Positive Patients. Mediators Inflamm. 2015; 2015:395484.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement